1995
Incidence and Risk Factors for Human T-Lymphotropic Virus Type II Seroconversion Among Injecting Drug Users in Baltimore, Maryland, U.S.A
Vlahov D, Khabbaz R, Cohn S, Galai N, Taylor E, Kaplan J. Incidence and Risk Factors for Human T-Lymphotropic Virus Type II Seroconversion Among Injecting Drug Users in Baltimore, Maryland, U.S.A. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1995, 9: 89-96. PMID: 7712239, DOI: 10.1097/00042560-199505010-00013.Peer-Reviewed Original ResearchConceptsRisk factorsDrug usersEnzyme immunoassayWestern blotHuman T-lymphotropic virusNeedle-sharing practicesRisk factor analysisT-lymphotropic virusMedian lag timeCase-control designALIVE studyRecent serumSeronegative IDUsStudy entryBaseline historyIncidence rateSeroconversionPositive casesSex partnersIDUsHTLVCalendar timeMonthsIncidenceBaseline
1994
The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users.
Astemborski J, Vlahov D, Warren D, Solomon L, Nelson K. The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. American Journal Of Public Health 1994, 84: 382-7. PMID: 8129052, PMCID: PMC1614821, DOI: 10.2105/ajph.84.3.382.Peer-Reviewed Original ResearchConceptsFemale intravenous drug usersIntravenous drug usersHIV seropositivityHIV infectionDrug usersHuman immunodeficiency virus (HIV) seroprevalenceIntravenous drug useDrug-using womenTrading of sexCohort studyVirus seroprevalenceDrug useCocaine useIntensive interventionLogistic regressionSeropositivityNumber of partnersMultivariate modelDrugsWomenSexInfectionGroupHigh levelsSeroprevalence